219 related articles for article (PubMed ID: 34401788)
1. Generation of hypoxia-sensing chimeric antigen receptor T cells.
Kosti P; Larios-Martinez KI; Maher J; Arnold JN
STAR Protoc; 2021 Sep; 2(3):100723. PubMed ID: 34401788
[TBL] [Abstract][Full Text] [Related]
2. Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors.
Fisher J; Sharma R; Don DW; Barisa M; Hurtado MO; Abramowski P; Porter L; Day W; Borea R; Inglott S; Anderson J; Pe'er D
Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506382
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors.
Kosti P; Opzoomer JW; Larios-Martinez KI; Henley-Smith R; Scudamore CL; Okesola M; Taher MYM; Davies DM; Muliaditan T; Larcombe-Young D; Woodman N; Gillett CE; Thavaraj S; Maher J; Arnold JN
Cell Rep Med; 2021 Apr; 2(4):100227. PubMed ID: 33948568
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
5. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
6. Paving New Roads for CARs.
Hyrenius-Wittsten A; Roybal KT
Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
[TBL] [Abstract][Full Text] [Related]
7. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
8. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
9. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
10.
Brakel BA; Chokshi CR; Salim SK; Venugopal C; Singh S
STAR Protoc; 2021 Dec; 2(4):100920. PubMed ID: 34761232
[TBL] [Abstract][Full Text] [Related]
11. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
12. Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry.
Xu C; Yin Y
Methods Mol Biol; 2020; 2108():159-165. PubMed ID: 31939179
[TBL] [Abstract][Full Text] [Related]
13. Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer.
Rotolo A; Atherton MJ; Kasper BT; Haran KP; Mason NJ
STAR Protoc; 2021 Dec; 2(4):100905. PubMed ID: 34746864
[TBL] [Abstract][Full Text] [Related]
14. Transwell migration assay to interrogate human CAR-T cell chemotaxis.
Oner A; Kobold S
STAR Protoc; 2022 Dec; 3(4):101708. PubMed ID: 36136753
[TBL] [Abstract][Full Text] [Related]
15. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
16. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
17. The making and function of CAR cells.
Zabel M; Tauber PA; Pickl WF
Immunol Lett; 2019 Aug; 212():53-69. PubMed ID: 31181279
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.
Schwerdtfeger M; Benmebarek MR; Endres S; Subklewe M; Desiderio V; Kobold S
Curr Hematol Malig Rep; 2021 Apr; 16(2):218-233. PubMed ID: 33939108
[TBL] [Abstract][Full Text] [Related]
19. Inducing T cell dysfunction by chronic stimulation of CAR-engineered T cells targeting cancer cells in suspension cultures.
Selli ME; Landmann JH; Arveseth C; Singh N
STAR Protoc; 2023 Mar; 4(1):101954. PubMed ID: 36607811
[TBL] [Abstract][Full Text] [Related]
20. Analysis of CAR-Mediated Tonic Signaling.
Calderon H; Mamonkin M; Guedan S
Methods Mol Biol; 2020; 2086():223-236. PubMed ID: 31707680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
